Monoclonal Antibodies (mAbs) or Single-Chain Antibodies are antibodies that are made by growing a recombinant cell line that produce multiple copies of a particular antibody molecule. Monoclonal antibodies (mAbs) are produced by immune cells that provide adaptive immunity, and they are engineered to have specificity against particular antigens. The name “monoclonal” refers to their production in a single immunized animal.
Highlighted with 83 tables and 84 figures, this 165-page report “Global Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global monoclonal antibodies market and all its sub-segments through extensively detailed classifications.
Global monoclonal antibodies market will reach $329.6 billion by 2030, growing by 10.9% annually over 2020-2030, driven by the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies.
Request Research Sample with Latest Industry Insights (165+ Pages Report): https://altusmarketresearch.com/reports/sample/29708
The Monoclonal Antibodies (mAbs) market is driven by factors such as the increasing demand for clinical trials, research and development of new drugs and products, increasing incidence of chronic diseases and lifestyle change in people.
Based on Source, the global Monoclonal Antibodies (mAbs) Market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Human
• Humanized
• Chimeric
• Murine
Based on Category, the global Monoclonal Antibodies (mAbs) Market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Branded mAbs
• Biosimilar mAbs
Based on Production Type, the global Monoclonal Antibodies (mAbs) Market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• In Vitro Production
• In Vivo Production
Based on Application, the global Monoclonal Antibodies (mAbs) Market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Cancer
o Breast Cancer
o Colorectal Cancer
o Lung Cancer
o Ovarian Cancer
o Other Cancer Types
• Autoimmune Diseases
• Inflammatory Diseases
• Infectious Diseases
• Other Applications
By End User, the global Monoclonal Antibodies (mAbs) Market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Hospitals
• Research Institutes
• Other End Users
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
AbbVie, Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co., Inc.
Mylan N.V
Norvatis AG
Pfizer
Sanofi S.A.
Monoclonal Antibodies (mAbs) Market: Geographically, the following regions together with the listed national/local markets are fully investigated:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa, Other Nations)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Source, Application, and End User over the forecast years are also included.
